Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Kidney Cancer Drugs Industry?

In the past few years, the market for kidney cancer drugs has experienced steady growth. It is projected to increase from $8.22 billion in 2024 to $8.53 billion in 2025, representing a compound annual growth rate (CAGR) of 3.8%. Various factors have contributed to this growth in the historical period, including increased spending on healthcare, a rapid increase in the aging population, a rise in pharmaceutical research and development expenses, and advancements in the discovery of cancer medications.

The market size of kidney cancer drugs is predicted to experience consistent growth in the ensuing years. It is anticipated to escalate to “$10.31 billion in 2029 with a compound annual growth rate (CAGR) of 4.8%. Factors contributing to this growth in the projection period include an increasing older population, heightened healthcare spending, increased mergers and collaborations in drug development, and the significant potential of developing economies. Major trends identified during this forecast period involve the adoption of 3D technology for drug production and model creation, investments in biomarkers, introduction or adoption of novel treatment methodologies, enhancement of treatment through precision medicine, investment in AI solutions, and alliances with other firms or government entities to expedite new drug development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp

#Which Factors Are Currently Driving The Growth Of The Kidney Cancer Drugs Market?

The increase in renal cancer cases serves as a primary driving force for the kidney cancer drugs market. Factors such as changes in lifestyle, tobacco usage, and unhealthy eating habits play a significant part in propelling the proliferation of these renal cancer cells. As per the American Cancer Society’s data in January 2022, a health organization striving to eradicate cancer in the US, it was projected that 79,000 new kidney cancer cases (50,290 males and 28,710 females) would be detected, and 13,920 individuals (8,960 males and 4,960 females) would succumb to the disease. Most diagnoses are found in individuals aged between 65 and 74, with an average diagnosis age being 64. Kidney cancer is exceedingly uncommon in individuals below the age of 45. Consequently, this augments the expansion of the kidney cancer drugs market.

The kidney cancer drugs market covered in this report is segmented –

1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)

2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products

3) By End Users: Hospitals, Clinics, Research Center, Other End-Users

Subsegments:

1) By Renal Cell Carcinoma (RCC): Targeted Therapies, Immune Checkpoint Inhibitors, Cytokine Therapies

2) By Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC): Chemotherapy Agents, Immunotherapy Agents, Antibody-Drug Conjugates (ADCs)

What Are The Leading Trends And Opportunities In The Kidney Cancer Drugs Sector?

Leading firms in the kidney cancer drugs market, such as Amneal Pharmaceuticals Inc., are concentrating on the development of biosimilars to improve treatment possibilities, make therapies more accessible and affordable, and encourage innovation in cancer care. Biosimilar development describes the creation of biological medicines that have high similarities to an existing approved product while ensuring comparable effectiveness, safety, and quality. To give an example, in November 2022, Amneal Pharmaceuticals Inc., an American pharmaceutical company, launched RELEUKO (filgrastim-ayow). This drug, which is a biosimilar to Neupogen (filgrastim), was developed by the same company to treat neutropenia, especially in patients receiving chemotherapy.

Who Are The Main Participants Shaping The Kidney Cancer Drugs Market Landscape?

Major companies operating in the kidney cancer drugs market include Pfizer Inc., Novartis AG, ExelixisInc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Amgen Inc ., Biocon Ltd, Rani Therapeutics, Eli Lilly and Company, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc, AVEO Oncology, Teva Pharmaceutical Industries Ltd., Kitov Pharma Limited, CureTech Ltd., Neopharma

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Which Region Currently Holds The Largest Share In The Kidney Cancer Drugs Market?

North America was the largest region in the kidney cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2591&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model